

19 MAY 2006
Docket No.: 029869.00004-US01
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Francis P. Kuhajda et al.

10/519804

Application No.: 10/519,804

Group Art Unit: Not Yet Assigned

Filed: December 29, 2004

Examiner: Not Yet Assigned

For: NOVEL COMPOUNDS, PHARMACEUTICAL
COMPOSITIONS CONTAINING SAME, AND
METHODS OF USE FOR SAME

INFORMATION DISCLOSURE STATEMENT

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08a/b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08a/b based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior

art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
 - ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).

- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i).
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.


- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO/SB/08a/b, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740, referencing Docket No. 029869.00004-US01.

Dated: May 19, 2006

Respectfully submitted,

By 
N. Whitney Wilson

Registration No.: 38,661
COVINGTON & BURLING
1201 Pennsylvania Avenue, N.W.
Washington, DC 20004-2401
(202) 662-6000
Attorney for Applicant

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/519,804-Conf.# 7358
				Filing Date	December 29, 2004
				First Named Inventor	Francis P. Kuhajda
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	029869.00004-US01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	BARAKAT, H. et al., Lipogenic Potential of Liver From Morbidly Obese Patients With and Without Non-Insulin-Dependent Diabetes, Metabolism, 40(3):280-285.	
	CB	DILS, R. et al., Fatty Acid Synthase from Rabbit Mammary Gland, Methods Enzymol., 35:74-83 (1975).	
	CC	FALO, L.D. et al., Cerulenin Is a Potent Inhibitor of Antigen Processing by Antigen-Presenting Cells, The Journal of Immunology, 139(12):3918-3923 (1987).	
	CD	FUNABASHI, H. et al., Binding Site of Cerulenin in Fatty Acid Synthetase, J. Biochem., 105(5):751-755 (1989).	
	CE	GOLDRICK, R.B. et al., Fatty Acid Synthesis De Novo in Human Adipose Tissue, Clinical Science and Molecular Medicine, 46:469-479 (1974).	
	CF	KUHAJDA, F.P. et al., Fatty Acid Synthesis: A potential Selective Target for Antineoplastic Therapy, Proc. Natl. Acad. Sci. USA, 91:6379-6383 (1994).	
	CG	KUNIEDA, T. et al., Highly Efficient Oxazolone-Derived Reagents for Beta-Lactam Formation from Beta-Amino Acids, Tetrahedron Letters, 29(18):2203-2206 (1988).	
	CH	LINN, T.C., Purification and Crystallization of Rat Liver Fatty Acid Synthetase, Archives of Biochemistry and Biophysics, 209(2):613-619 (1981).	
	CI	MOELLING, K. et al., In vitro Inhibition of HIV-1 Proteinase by Cerulenin, Federation of European Biochemical Societies, 261(2):373-377 (1990).	
	CJ	OMURA, S., The Antibiotic Cerulenin, a Novel Tool for Biochemistry as an Inhibitor of Fatty Acid Synthesis, Bacteriological Reviews, 40(3):681-697 (1976).	
	CK	OMURA, S. et al., Triacsins, New Inhibitors of Acyl-CoA Synthetase Produced by Streptomyces Sp., The Journal of Antibiotics, XXXIX(9):1211-1218 (1986).	
	CL	PEREZ, L. et al., Cerulenin, an Inhibitor of Lipid Synthesis, Blocks Vesicular Stomatitis Virus RNA Replication, Federation of European Biochemical Societies, 280(1):129-133 (1991).	
	CM	RONCARI, D.A.K., Mammalian Fatty Acid Synthetase, I. Purification and Properties of Human Liver Complex, Can. J. Biochem., 52:221-230 (1974).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/519,804-Conf. #7358
				Filing Date	December 29, 2004
				First Named Inventor	Francis P. Kuhajda
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	029869.00004-US01

	CN	SASAKI, H. et al., Thiolactomycin, a New Antibiotic, II. Structure Elucidation, The Journal of Antibiotics, XXXV(4):396-400 (1982).	
	CO	SIMON, S.M. et al., Myristoylation of Proteins in the Yeast Secretory Pathway, The Journal of Biological Chemistry, 267(6):3922-3931 (1992).	
	CP	STRIJTVEEN, B. et al., Synthesis and Determination of Enantiomeric Excesses of Non-Racemic <i>Tert</i> -Thiols Derived from Chiral Secondary α -Mercaptocarboxylic Acids, Tetrahedron, 43(21):5039-5054 (1987).	
	CQ	THOMPSON, B.J. et al., Biosynthesis of Fatty Acids by Lactating Human Breast Epithelial Cells: An Evaluation of the Contribution to the Overall Composition of Human Milk Fat, Pediatric Research, 19(1):139-143.	
	CR	TOMODA, H. et al., Evidence for an Essential Role of Long Chain Acyl-CoA Synthetase in Animal Cell Proliferation, The Journal of Biological Chemistry, 266(7):4214-4219 (1991).	
	CS	TOMODA, H. et al., Inhibition of Acyl-CoA Synthetase by Triacins, Biochimic et Biophysica Acta, 921:595-598 (1987).	
	CT	TRISCARI, J. et al., Changes in Lipid Metabolism in Diet-Induced Obesity, Metabolism, 34(6):580-587 (1985).	
	CU	WAKIL, S.J., Fatty Acid Synthase, A Proficient Multifunctional Enzyme, Biochemistry, 28(11):4523-4530 (1989).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--